Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Jan 11, 2018 at 9:50 AM EST

Short Sellers Grow More Selective on Major Biotechs

The December 29 short interest data have been compared with the previous report, and short interest in the selected biotech…

Chris Lange | Jan 11, 2018 at 9:45 AM EST

Major Pharma Short Interest Takes a Plunge

The December 29 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jan 8, 2018 at 10:50 AM EST

Why Alder Biopharma Is Winning Big on Monday

Alder Biopharmaceuticals saw its shares make a solid gain on Monday amid a blizzard of updates from the company.

Chris Lange | Jan 8, 2018 at 10:10 AM EST

Axovant Crumbles Following Alzheimer’s Study Update

Axovant Sciences watched its shares practically get halved in Monday’s session after the firm provided an update from a few…

Chris Lange | Jan 6, 2018 at 8:55 AM EST

20 More Biopharma Catalysts Coming in 2018

Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves…

Paul Ausick | Jan 5, 2018 at 12:45 PM EST

Is the World Health Organization Kicking Older People to the Curb?

The World Health Organization does not refer to the illnesses and conditions of people older than 60 in its draft…

Chris Lange | Jan 5, 2018 at 12:10 PM EST

Investors Cheer Secondary Offering for Gene-Editing Firm

While most secondary offerings would bring down the price of the stock, this case is different and shareholders are cheering…

Chris Lange | Jan 5, 2018 at 11:15 AM EST

Meet Merrill Lynch’s Top Biotech Picks for 2018

Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and…

Chris Lange | Jan 4, 2018 at 12:30 PM EST

Audentes Therapeutics Pulls Off Positive Interim Results

Audentes Therapeutics shares made a handy gain on Thursday after the company announced positive interim data for a midstage trial.

Chris Lange | Jan 4, 2018 at 11:30 AM EST

Rite Aid Whiffs Big on Q3 Revenues

Shares of Rite Aid stumbled after the specialty retailer released mixed quarterly results late on Wednesday.

Lee Jackson | Jan 4, 2018 at 10:45 AM EST

Stifel Has 5 Specialty Pharmaceutical 2018 Buys With Massive Upside Potential

24/7 Wall St. screened the Stifel specialty pharmaceutical list and found five stock rated Buy that have massive upside potential…

Chris Lange | Jan 4, 2018 at 9:10 AM EST

2018 Bull/Bear Outlook Pfizer and Merck: Where Does Major Health Care Go From Here?

For the Jones Industrial Average to make its 2018 targets, Pfizer and Merck will to have to do their part…

Chris Lange | Jan 3, 2018 at 10:45 AM EST

Sangamo Jumps on Newest Pfizer Collaboration

Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with…

Chris Lange | Jan 3, 2018 at 10:35 AM EST

Trevena Surges With FDA Decision

Trevena saw its shares make a handy gain to start out Wednesday after the firm announced that the FDA accepted…

Lee Jackson | Jan 2, 2018 at 8:20 AM EST

4 Biotech Stocks to Buy for 2018 With Up to 100% Upside Potential

We screened our 24/7 Wall St. research database for hot biotech ideas and found four companies that are offering big…

1 … 145 146 147 148 149 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Grow More Selective on Major Biotechs

Major Pharma Short Interest Takes a Plunge

Why Alder Biopharma Is Winning Big on Monday

Axovant Crumbles Following Alzheimer’s Study Update

20 More Biopharma Catalysts Coming in 2018

Is the World Health Organization Kicking Older People to the Curb?

Investors Cheer Secondary Offering for Gene-Editing Firm

Meet Merrill Lynch’s Top Biotech Picks for 2018

Audentes Therapeutics Pulls Off Positive Interim Results

Rite Aid Whiffs Big on Q3 Revenues

Stifel Has 5 Specialty Pharmaceutical 2018 Buys With Massive Upside Potential

2018 Bull/Bear Outlook Pfizer and Merck: Where Does Major Health Care Go From Here?

Sangamo Jumps on Newest Pfizer Collaboration

Trevena Surges With FDA Decision

4 Biotech Stocks to Buy for 2018 With Up to 100% Upside Potential

AMZW’s Weekly Payouts Drop 79% as Volatility Collapses; Can Investors Count on Them?

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

AMZW’s Weekly Payouts Drop 79% as Volatility Collapses; Can Investors Count on Them?

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Grow More Selective on Major Biotechs

Major Pharma Short Interest Takes a Plunge

Why Alder Biopharma Is Winning Big on Monday

Axovant Crumbles Following Alzheimer’s Study Update

20 More Biopharma Catalysts Coming in 2018

Is the World Health Organization Kicking Older People to the Curb?

Investors Cheer Secondary Offering for Gene-Editing Firm

Meet Merrill Lynch’s Top Biotech Picks for 2018

Audentes Therapeutics Pulls Off Positive Interim Results

Rite Aid Whiffs Big on Q3 Revenues

Stifel Has 5 Specialty Pharmaceutical 2018 Buys With Massive Upside Potential

2018 Bull/Bear Outlook Pfizer and Merck: Where Does Major Health Care Go From Here?

Sangamo Jumps on Newest Pfizer Collaboration

Trevena Surges With FDA Decision

4 Biotech Stocks to Buy for 2018 With Up to 100% Upside Potential

AMZW’s Weekly Payouts Drop 79% as Volatility Collapses; Can Investors Count on Them?

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how